First human test of new depression pill checks safety
Knowledge-focused
Completed
This early-stage study aimed to check the safety and side effects of a new oral drug called AGN-241751 (zelquistinel), which is being developed for major depressive disorder. It involved 68 healthy volunteers who received a single dose of the drug or a placebo. The main goal was …
Phase: PHASE1 • Sponsor: Syndeio Biosciences, Inc • Aim: Knowledge-focused
Last updated Apr 01, 2026 14:42 UTC